In 1988, Seattle Genetics was co-founded by Clay B.Siegall, the company’s Chief Executive Officer, President and Chairman of the Board. Dr. Siegall is a trained scientist specializing in targeted cancer research. He attended George Washington University and obtained a Ph.D in genetics and the University of Maryland where he got his B.S. in Zoology.
Seattle Genetics stands for thorough research, scientific innovation and drug development and is comprised of employees who have a passion for helping their patients. Clay practices a strong leadership in developing antibody drug conjugulates (ADCs) and in obtaining the 2011 FDA approval of its first ADC product, ADCETRIS(brentuximab vedotin). ADCETRIS is now a globally known brand that has been approved in over 60 countries. Seattle Genetics is continuing to expand its proprietary ADCs in order to help treat cancer.
Seattle Genetics is a biotechnology company that is working hard to develop technology designed to harness the targeting ability of monoclonal antibodies to get cell-killing agents directly to cancer cells. ADCs help spare non-targeted cells and reduce many of the toxic effects of chemotherapy.
Seattle Genetics has obtained multiple licenses for its ADC technology, including but not limited to Genentech(Roche), AbbVie, GlaxoSmithKline and Pfizer, that have accumulated more than $325 million thus far in clinical development. There are more than 20 ADCs using Seattle Genetics’ technology. Dr.Siegall has had a large part in raising capital through venturous endeavors, securing more than $1.2 billion through private and public financings.
From 1991 to 1997 and before co-founding Seattle Genetics, Dr. Siegall was associated with the Bristol-Myers Squibb Pharmaceutical Research Institute and the National Cancer Institute of Health. He is currently on the boards of Directors of Ultragenyx Pharmaceutical, Alder BioPharmaceuticals, Mirma Therapeutics and Washington Roundtable. Dr.Siegall has received many notable awards, including the 2012 Pacific Northwest Ernst & Young Entrepreneur of the year and the 2013 University of Maryland Alumnus of the Year for Computer, Math and Natural Sciences. Siegall currently holds 15 patents and is author to more than 70 publications and continues to fight cancer with his vast amount of knowledge and experience.